We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
News

Amgen's Parasabiv Rejected by FDA

Rectangle Image
News

Amgen's Parasabiv Rejected by FDA

Read time:
 

Amgen has announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the New Drug Application (NDA) for Parsabiv™ (etelcalcetide) for the treatment of secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. 

The correspondence of a Complete Response Letter means that the FDA has decided that they will not approve Parsabiv in its present form.

Amgen is reviewing the Complete Response Letter, and anticipate a post-action meeting with the FDA later this year to discuss the Complete Response.

Amgen claim that the Complete Response Letter does not impact their regulatory submissions in other regions.

Advertisement